These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22302255)

  • 1. Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy.
    Banh HL; Trevoy J; Pabst H; Beach J; Vethanayagam D
    Am J Health Syst Pharm; 2012 Feb; 69(4):302-6. PubMed ID: 22302255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
    Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
    J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of omalizumab in non-allergic severe asthma.
    Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
    J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis?
    Latorre M; Baldini C; Seccia V; Notarstefano C; Della Rossa A; Tani C; Talarico R; Mosca M; Paggiaro PL
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S91-2. PubMed ID: 23075542
    [No Abstract]   [Full Text] [Related]  

  • 10. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R; Marco AG; Cohen D; Canonica GW
    Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.
    Brodlie M; McKean MC; Moss S; Spencer DA
    Arch Dis Child; 2012 Jul; 97(7):604-9. PubMed ID: 22685051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D; Talker O; Metabichek A; Yaakovi I
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma.
    Yalcin AD; Bisgin A; Cetinkaya R; Yildirim M; Gorczynski RM
    Clin Lab; 2013; 59(1-2):71-7. PubMed ID: 23505909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful desensitization of three patients with hypersensitivity reactions to omalizumab.
    Owens G; Petrov A
    Curr Drug Saf; 2011 Nov; 6(5):339-42. PubMed ID: 22424542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of an asthma patient receiving omalizumab during pregnancy].
    Hirashima J; Hojo M; Iikura M; Hiraishi Y; Nakamichi S; Sugiyama H; Kobayashi N; Kudo K
    Arerugi; 2012 Nov; 61(11):1683-7. PubMed ID: 23328225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.